Characteristic Clinical Manifestations of Antiphospholipid Syndrome
Antiphospholipid syndrome is characterized by recurrent venous thrombosis (a), recurrent miscarriages (b), and livedo reticularis (e). Anti-CCP antibodies and elevated homocysteine levels are not defining features of APS.
Core Clinical Features
According to the most recent 2021 AHA/ASA guidelines, APS is definitively characterized by persistent antiphospholipid antibodies (tested 12 weeks apart) plus clinical criteria including vascular thrombosis or pregnancy morbidity 1. The syndrome encompasses both thrombotic and obstetric manifestations:
Thrombotic Manifestations
- Venous thrombosis is the most frequently reported manifestation, often presenting as deep vein thrombosis with or without pulmonary embolism 2
- Arterial thrombosis, most commonly cerebrovascular accidents (stroke or transient ischemic attacks) 2
- Small vessel thrombosis affecting multiple organ systems 3, 4
Obstetric Manifestations
- Recurrent fetal loss, typically second- or third-trimester miscarriages 2
- Early pregnancy loss
- Premature births due to severe pre-eclampsia or placental insufficiency 4
Associated Non-Criteria Manifestations
The guidelines explicitly identify several additional clinical features that are "relatively common" in APS patients 2:
- Livedo reticularis - a characteristic mottled skin pattern 2
- Thrombocytopenia 2, 3, 4
- Cardiac valve alterations/disease 2, 3, 4
- Painful leg ulcerations 2
- False-positive VDRL test results 2
- Hemolytic anemia 3, 4
- Renal thrombotic microangiopathy 3, 4
- Cognitive impairment 3, 4
What APS is NOT Characterized By
Anti-CCP Antibodies (Option c)
Anti-CCP (anti-cyclic citrullinated peptide) antibodies are NOT associated with APS. These antibodies are specific markers for rheumatoid arthritis, not antiphospholipid syndrome. This is a completely different autoimmune condition with distinct pathophysiology.
High Homocysteine Levels (Option d)
While elevated homocysteine is mentioned in the guidelines as a risk factor for stroke in childhood that can cause a hypercoagulable state 2, it is not a defining characteristic of APS. Homocystinuria is described as a separate, uncommon cause of arterial and venous occlusion with its own distinct clinical features (marfanoid appearance, malar flushing, ectopia lentis) 2. The guidelines clearly distinguish between APS and other hypercoagulable states including elevated homocysteine levels.
Clinical Pearls
The "triple-positive" antibody profile (lupus anticoagulant, anticardiolipin, and anti-β2 glycoprotein-I) identifies the highest-risk patients and has important treatment implications, particularly regarding the contraindication of rivaroxaban 1.
APS can be primary (isolated condition) or secondary (associated with systemic lupus erythematosus or other rheumatological disorders) 2.
The syndrome affects younger populations more commonly, with approximately 13% of APS patients presenting with stroke as their initial clinical manifestation 1.
Correct answers: a, b, and e